Clinical Experience of Dienogest in Perimenopausal Females With Symptomatic Adenomyosis

202207140RINB

Between September 2018 and December 2021, women who did not want further childbearing and received dienogest treatment for dysmenorrhea and/or hypermenorrhea were included in a retrospective chart review. Dienogest 2mg was prescribed once per day orally after completing the above-mentioned exam. The patient would return to our clinic on the 1st, 3rd, and 6th then every 3 months for a prescription. The primary outcome was successfully long-term (more than a year) dienogest use for pain and/or bleeding control. The secondary outcomes were the reasons for discontinuing dienogest treatment and the predictor of successful long-term treatment.

2018-09-01

2021-12-31

2021-12-31

Completed

87

Inclusion Criteria: * Women with adenomyosis who did not want further childbearing and received dienogest treatment for dysmenorrhea and/or hypermenorrhea Exclusion Criteria: * \< 40 y/o * Post-operative prevention of endometriosis recurrence * Medical conditions not suitable for dienogest treatment, such as known breast cancer, high thromboembolic effect, and smoking

{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'RETROSPECTIVE'}, 'enrollmentInfo': {'count': 87, 'type': 'ACTUAL'}}

2023-03-02